EZH2 Supports Osteoclast Differentiation and Bone Resorption Via Epigenetic and Cytoplasmic TargetsJuraj Adamik(Merck & Co., Inc., Rahway, NJ, USA (United States)), Deborah L. Galson(University of Pittsburgh)Journal of Bone and Mineral ResearchSeptember 5, 201910.1002/jbmr.3863Cited by 42SaveCiteExport RISWatch citationsRelated PapersAbstract 2485: A combined mregDC and Treg signature associates with antitumor efficacy of CCR4 antagonist tivumecirnon FLX475|Cancer Research|2024|1